Short communication: The cost-effectiveness of cutaneous leishmaniasis patient management during an epidemic in Chaparral, Colombia in 2004.

Abstract

We calculated ranges for the cost per disability adjusted life year (DALY) averted for cutaneous leishmaniasis (CL) treatment during an ongoing epidemic of CL in Chaparral, Colombia. Using operational clinical and cost data, we calculated that the cost of treating leishmaniasis patients with standard pentavalent antimony was US$345 (95% CI 277-488) per patient treated and cured. The cost per DALY averted per patient cured with antimony was estimated to be approximately US$15 000 (95% CI 12 226-21 532).

• Authors: Juan Carlos Vega, Boris Fernando Sanchez, Luz Mery Montero, Rafael Montaña, Mercedes Del Pilar Mahecha, Bladimir Dueñes, Angela Rocío Baron, Richard Reithinger
• Journal: Tropical medicine & international health : TM & IH (Trop Med Int Health) Vol. 12 Issue 12 Pg. 1540-4 (Dec 2007) ISSN: 1365-3156 [Electronic] England
• PMID: 18076562 (Publication Type: Journal Article)

Chemical References

• Antiprotozoal Agents
• Organometallic Compounds
• Meglumine
• Meglumine Antimoniate

Topics

• Antiprotozoal Agents (economics, therapeutic use)
• Colombia (epidemiology)
• Cost-Benefit Analysis
• Disease Outbreaks (economics)
• Hospital Costs (statistics & numerical data)
• Humans
• Leishmaniasis (drug therapy, economics, epidemiology)
• Meglumine (economics, therapeutic use)
• Meglumine Antimoniate
• Organometallic Compounds (economics, therapeutic use)